We need your support!

Looking for participants for a clinical trial

Randomized phase II clinical trial of mycophenolate mofetil in mild interstitial lung disease associated with systemic scleroderma.

CHUM rheumatologist Dr. Sabrina Hoa’s research team is looking for participants with scleroderma and mild interstitial lung disease for a clinical trial. This pilot study will evaluate the efficacy of mycophenolate mofetil (an immunosuppressive drug) initiated early in the mild phase of lung disease, compared with placebo.

Study participation criteria.

 

Registration and information form

For new and current participants, please complete the registration and information update form by clicking here.  Once completed, please send the form by email to info@sclerodermie.ca or by mail to:

Scleroderma Quebec
40-550 chemin Chambly
Longueuil QC J4H 3L8

 

Notice to healthcare professionals

A clinical trial in scleroderma is currently recruiting at the CHUM. (VITALISScE™ Trial)

Please read the details of this clinical trial (VITALISScE™) being conducted in the province of Quebec by Dr Sabrina Hoa’s team at the CHUM.  Read more

 

Scleroderma Quebec: Your Online Resource for Understanding and Managing Scleroderma

Discover Scleroderma Quebec’s online platform, designed to help people living with scleroderma better understand their condition and find relevant information on symptoms, treatments, and research advancements, primarily in Quebec and Canada. Our site offers videos, informational sheets, and patient forums open to everyone…Read more

 

Discover our educational sheets on scleroderma

At Sclerodermie Quebec, our mission is to support you in your understanding of scleroderma. In collaboration with health specialists, we have developed a series of educational sheets to enlighten you about this complex condition. These resources cover, among other things:

  • The basic principles of scleroderma, its manifestations, and treatment options.
  • A detailed analysis of the symptoms for a better understanding of their impacts.
  • The importance of emotional support and the value of support networks for living with resilience and hope.

These sheets are a complement to the advice of your health specialist, enriching your dialogue with professionals and helping you take an active role in your care journey.

We invite you to explore our educational sheets, designed to simplify access to information and equip you with the necessary tools for a comprehensive approach to managing scleroderma. Join our community to benefit from ongoing support and progress together, enriched by a network of mutual aid and knowledge exchange… Read more

 

Scleroderma Quebec Support Groups

Explore the scleroderma support groups offered by Scleroderma Québec, led by trained volunteers who often are sufferers themselves. These spaces foster mutual support and provide strategies for managing life with the disease, welcoming newly diagnosed individuals, caregivers, or long-standing patients.

Commitment and Safety: Sessions focused on validated information about symptoms and treatments aim to strengthen your support network and enhance daily management of scleroderma. They assist in confidently navigating the disease’s complexities.

Important Notice for Participants: While providing emotional support and facilitating the exchange of experiences, our groups do not substitute for professional medical advice. Promoting treatments not approved by scleroderma specialists is prohibited, underscoring our commitment to practices validated by recognized experts.

For more information…Read more

 

Autoantibodies in scleroderma

Scleroderma is a complex disease that is the subject of extensive research to understand the pathogenic mechanisms and identify new therapeutic targets. This article focuses on the dysfunction of the immune system, specifically the particular antibodies found in the blood of people with scleroderma…Read more

 

Every donation counts

With your support, we can fight scleroderma!

 


 

Testimonies

Discover the stories of people with the disease.

Last updated : October 27, 2024